Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

DEM BioPharma

Request full access

Immuno-oncology therapies targeting innate immune system checkpoints

Cambridge, United StatesFounded 2022Biotech & Life Sciences

About DEM BioPharma

DEM BioPharma, Inc. is a biotechnology company focused on developing immunotherapies that target the innate immune system to combat cancer. Founded in 2022 and based in Cambridge, Massachusetts, the company launched with a $70 million Series A financing round led by Longwood Fund and Alta Partners, with participation from notable investors including Pfizer Ventures and Insight Partners. The company's scientific foundation is built upon the research of its co-founders: Dr. Jonathan Weissman of the Whitehead Institute, Dr. Michael Bassik of Stanford University, and Dr. Kipp Weiskopf of the Whitehead Institute and Dana-Farber Cancer Institute. Other co-founders include Christoph Westphal and David Donabedian, who also served as the start-up CEO. Nenad Grmusa was appointed CEO in September 2022.

The company's core business revolves around its proprietary CHoMP™ (Co-culture with Human Myeloid Phagocytes) platform. This platform utilizes inter-cellular CRISPR screening to systematically identify and validate novel "don't eat me" (DEM) and "eat me" (EM) signals on cancer cells and macrophages. By targeting these signals, DEM BioPharma aims to unleash the power of macrophages and other myeloid effector cells to recognize and eliminate tumors, a largely untapped area in immuno-oncology. The platform has successfully identified several new DEM/EM signals, including the APMAP pathway, which demonstrated enhanced tumor cell phagocytosis in preclinical models.

DEM BioPharma's business model is focused on the discovery, development, and eventual commercialization of novel cancer therapies. Its pipeline includes programs targeting newly identified pathways. For example, DEM-T02 is a glycoprotein overexpressed in several solid tumors, and the company is developing DEM301, an antibody-drug conjugate (ADC) targeting it. Another program, DEM-T06, focuses on an intracellular target in myeloid cells to activate pro-inflammatory responses against tumors. The company operates in the competitive immuno-oncology market, aiming to develop a new generation of macrophage checkpoint inhibitors that could significantly change cancer treatment paradigms.

Source: Dealroom company data

At a glance

Status
Operational
Employees
20
Open positions
None listed
Dealroom signal
68.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Jun 2022 $70M $280M Insight Partners · Astellas Venture · Alexandria Venture Investments · UTokyo Innovation Platform ↗
SPINOUTOther financing Jan 2022 $0 — The University of Tokyo —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

DEM BioPharma website traffic

Latest recorded traffic for DEM BioPharma is 1.9K monthly website visits, up 118.4% over the last three months. DEM BioPharma's team declined 4.8% over the past year.

Latest monthly visits1.9K 3-month web change+118.4% 1-year team growth-4.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

DEM BioPharma in the Cambridge ecosystem

Live from Dealroom

The DEM BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

Other known investors1 additional known investor

  • The University of Tokyo
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States95.2%
🇯🇵 Japan4.8%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about DEM BioPharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See DEM BioPharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.